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Background
Triple negative breast cancer (TNBC) is a heterogeneous
subgroup (ER-, PR-, and HER2-) of invasive breast can-
cer, associated to poor prognosis, partially due to its
resistance to available drugs. Therefore, it is imperative
to discover new treatment options for the disease. In
this context, we have synthesized and screened novel
naphtoquinone-derived drugs (patent-protected), ration-
ally designed to act through multiple pathways to avoid
tumor chemoresistance.
Methods
Drugs antineoplastic efficacy (AE) was accessed in the
claudin-low TNBC cell line, MDA-MB231, by cellular
metabolic viability (CMV) and IC50 calculation (MTT
method; GraphPad Prism version 5.1). Drugs toxicity was
studied in healthy mice, following the Guideline 423 (for
test of chemicals) of OECD; blood cells and tissues were
analyzed by a Pathologist. Computational molecular dock
studies were conducted to investigate the molecules tridi-
mensional conformation and bounding energy to topoi-
somerase 2 (TOPO) and PI3K (Autodock Vina software).
Results and conclusions
We screened the AE of 43 novel drugs in MDA-MB231
(CMV ≤ 50% with 7 drugs). Of these, the most promising
drugs PIC 20 (IC50 1.38x10
-5M; CMV = 10%) and PIC21
(IC50 5.00x10
-5M; CMV = 30%) showed significantly
higher AE than cisplatin (IC50 1.56x10
-4M; CMV>90%),
doxorubicin (IC50 1.76x10
-4M; CMV = 62%), and pacli-
taxel (IC50 5.05x10
-7M; CMV = 80%). None of the treated
mice died, neither demonstrated symptoms of toxicity, fol-
lowing 14-days treatment with PIC. Indeed, there was no
significant change in the animals’ weight and general activ-
ity/behavior. Major organs showed no significant morpho-
logical changes, congestion, edema, necrosis, degeneration
or inflammation. On the other hand, there was a 48.98%
decrease in their hematocrit count. Finally, based on the
crystalline structure of proteins deposited on PDB (1QZR,
TOPO; 1E7U, PI3K), and PIC20 and PIC21 tridimensional
structures, we concluded that the novel molecules bind to
the ATP domain of the proteins with similar interaction
energy (E) than the TOPO - Doxorubicin (E = -5.6) and
Etoposide (E = -5.7) - or PI3K inhibitors - LY294002 (E =
-9.5) and Wortmannin (E = -8.8): PIC20: E = -5.3 and -8.9;
PIC21: E = -5.7 and -8.2, for TOPO and PI3K, respectively.
In conclusion, we present novel and potentially safe drugs
to treat TNBC, in an innovative and economically viable
approach.
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